Xuanzhu Biopharm Co Ltd (2575) fair value: what the stock is really worth
As of Nov 18, 2026: fair value (intrinsic value) of Xuanzhu Biopharm Co Ltd stock HK$1.42, price HK$7.70, that is 81.6% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Xuanzhu Biopharm Co Ltd
2575 · HKFar too expensive (fair value 82% below the price) and falling price, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 19, 2026.
How to read this chart
13‑month range HK$7.70 – HK$82.95 · fair‑value band HK$0.9400 – HK$1.78 · the HK$7.70 price screens above the HK$1.42 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 19, 2026.
Every Wednesday you see whether Xuanzhu Biopharm Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China.
Show moreShow less
Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
The company also develops KM501, a first-in-class HER2/HER2 bispecific antibody drug conjugate, which is in Phase I clinical trial; KM602, which is in Phase I clinical trial for anti-tumor; XZP-7797, a selective and brain-penetrating poly ADP-ribose polymerase 1 inhibitor; and XZP-6924, a ubiquitin-specific protease 1 (USP1) inhibitor.
In addition, it develops XZB-0004, an oral small molecule anexelekto inhibitor; XZP-6877, a DNA-dependent protein kinase inhibitor; NG-350A, a next-generation oncolytic viral therapy; XZP-5610, a non-steroid farnesoid X receptor; and XZP-6019, a first-in-class ketohexokinase (KHK) inhibitor.
The company was founded in 2008 and is headquartered in Beijing, China. Xuanzhu Biopharmaceutical Co., Ltd. is a former subsidiary of Sihuan Pharmaceutical Holdings Group Ltd.
Stock analysis
Xuanzhu Biopharm Co Ltd (2575) currently trades at HK$7.70, while our model-based Fair Value estimate is HK$1.42, 82% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the data coverage at low.
Scenario range: HK$0.9400 (bear) to HK$1.78 (bull), the price of HK$7.70 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Xuanzhu Biopharm Co Ltd reported revenue of 56.1M CNY in FY2025 versus 32.0K CNY in FY2023, a compound +4,085.9%/yr. Reported net income was −266M CNY in FY2025.
Key figures
Market cap HK$4.0B (≈ $512M) Small · P/S ratio 43.4 · EPS (TTM) HK$−0.2500 · Return on equity −19.6% · Return on assets (EBIT) −29.6% (5-year average) · Operating margin −114% · Revenue (TTM) 103M CNY · Revenue growth (YoY) +288%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (low confidence).
What moves the price
The share trades about 91% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −82%, 2575 screens richer than that median.
Fair Value models
All 1 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
2575 screens overvalued: fair value 82% below the price. Compare with Merck KGaA →
Compare Xuanzhu Biopharm Co Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 608 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $85.57 | $113.53 | +33% | vs 2575 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥46.90 | ¥52.43 | +12% | vs 2575 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,872 | ₹1,983 | +6% | vs 2575 |
| Haleon plc HLN | $9.08 | $8.47 | −7% | vs 2575 |
| Merck KGaA MRK | €149.50 | €108.83 | −27% | vs 2575 |
| Galderma Group GALD | CHF 187.55 | CHF 112.46 | −40% | vs 2575 |
| Takeda Pharmaceutical Company TAK | $21.27 | $11.23 | −47% | vs 2575 |
| Sandoz Group SDZ | CHF 81.50 | CHF 41.06 | −50% | vs 2575 |
| Teva Pharmaceutical Industries Limited TEVA | $42.23 | $20.74 | −51% | vs 2575 |
| Divi's Laboratories Limited DIVISLAB | ₹11,049 | ₹1,567 | −86% | vs 2575 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Xuanzhu Biopharm Co Ltd (2575) overvalued or undervalued?
What is the fair value of 2575?
What is the quality score of 2575?
What is the price target for Xuanzhu Biopharm Co Ltd (2575)?
What is the Xuanzhu Biopharm Co Ltd stock forecast for 2026?
What is the revenue of Xuanzhu Biopharm Co Ltd (2575)?
What is the intrinsic value of Xuanzhu Biopharm Co Ltd (2575)?
Is Xuanzhu Biopharm Co Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2575?
How much is Xuanzhu Biopharm Co Ltd worth?
What do the bullish and bearish scenarios say about 2575?
How solid is the balance sheet of Xuanzhu Biopharm Co Ltd (2575)?
How far is 2575 from its 52-week high?
Which stocks are comparable to Xuanzhu Biopharm Co Ltd?
Is Xuanzhu Biopharm Co Ltd stock attractive at the current price?
How is the fair value of 2575 calculated?
Is it still worth investing in stocks now?
What is the share price of Xuanzhu Biopharm Co Ltd (2575)?
What should I pay attention to with Xuanzhu Biopharm Co Ltd right now?
Key figures of Xuanzhu Biopharm Co Ltd
How large is the market capitalisation of Xuanzhu Biopharm Co Ltd (2575)?
What is the P/S ratio of Xuanzhu Biopharm Co Ltd (2575)?
What are the earnings per share of Xuanzhu Biopharm Co Ltd (2575)?
What is the return on equity of Xuanzhu Biopharm Co Ltd (2575)?
What is the EBIT return on assets of Xuanzhu Biopharm Co Ltd (2575)?
What is the operating margin of Xuanzhu Biopharm Co Ltd (2575)?
How fast is revenue growing at Xuanzhu Biopharm Co Ltd (2575)?
How much free cash flow does Xuanzhu Biopharm Co Ltd (2575) generate?
How much net cash does Xuanzhu Biopharm Co Ltd (2575) hold?
Watch Xuanzhu Biopharm Co Ltd in the live analysis
One click puts Xuanzhu Biopharm Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.